As The World Moves Faster, So Should We
Climate change, urbanization, and international travel contribute to the risk of infectious diseases globally.1 At Bavarian Nordic, we are driven to find vaccine solutions to help combat the threat of infectious diseases.
Committed to Helping Save and Improve Lives
![about-commit-1](/sites/us.bnhcp.com/files/styles/large/public/2024-03/about-commit-1.png?itok=rCuNzNQp)
Providing disease awareness and education
![about-commit-2](/sites/us.bnhcp.com/files/styles/large/public/2024-03/about-commit-2.png?itok=92V-Etvd)
Expanding production capabilities to ensure reliable manufacturing and supply of vaccines
![about-commit-3](/sites/us.bnhcp.com/files/styles/large/public/2024-03/about-commit-3.png?itok=eXSR369S)
Applying our innovative spirit to continue leadership in infectious diseases and travel health
![about-commit-4](/sites/us.bnhcp.com/files/styles/large/public/2024-03/about-commit-4.png?itok=WZb_NgXF)
Being a trusted partner for your vaccine needs
Building on a Legacy of Vaccine Achievements
![Ellipse 5-0](/sites/us.bnhcp.com/files/styles/large/public/2024-03/Ellipse%205-0.png?itok=rRRPny-C)
1994
Founded in Denmark
![Ellipse 5-1](/sites/us.bnhcp.com/files/styles/large/public/2024-03/Ellipse%205-1.png?itok=2Qp82XXU)
2007
First smallpox supply contract with US Government
![Ellipse 5-2](/sites/us.bnhcp.com/files/styles/large/public/2024-03/Ellipse%205-2.png?itok=1HQP0c3A)
2014
Entered collaboration with Janssen for development and supply of Ebola vaccine
![Ellipse 5-3](/sites/us.bnhcp.com/files/styles/large/public/2024-03/Ellipse%205-3.png?itok=ebs7NsnB)
2019
Approval in the United States for Smallpox and Monkeypox Vaccine, Live, Non-replicating suspension for subcutaneous injection
![Ellipse 5-4](/sites/us.bnhcp.com/files/styles/large/public/2024-03/Ellipse%205-4.png?itok=yyHpP0ec)
2020
US Commercial team established; acquisition of Rabies Vaccine
![Ellipse 5-5](/sites/us.bnhcp.com/files/styles/large/public/2024-03/Ellipse%205-5.png?itok=9vDBKP2G)
2023
Acquisition of Typhoid Vaccine Live Oral Ty21a, Cholera Vaccine Live Oral, and a Phase 3 vaccine candidate for the prevention of chikungunya virus from Emergent BioSolutions
With pride in our achievements in vaccine development over the past 30 years, we are focused on the future. Right now, we are working on bringing patients around the globe an even greater degree of protection from infectious diseases.
An Evolving Vaccines Portfolio That Addresses Global Health Risks and Unmet Needs
![about-vaccines-1](/sites/us.bnhcp.com/files/styles/large/public/2024-03/about-vaccines-1_0.png?itok=oEnHh_D0)
RABIES2,3
Found on all continents, except Antarctica Causes ~59,000 deaths globally each year and is nearly 100% fatal once clinical symptoms appear
![about-vaccines-2](/sites/us.bnhcp.com/files/styles/large/public/2024-03/about-vaccines-2_0.png?itok=Er9uEKnf)
TYPHOID5
~11–21 million cases of typhoid fever occur worldwide each year, with ~85% of cases in the US occurring among international travelers
~135,000–230,000 deaths are attributed to typhoid and paratyphoid fever worldwide each year
![about-vaccines-3](/sites/us.bnhcp.com/files/styles/large/public/2024-03/about-vaccines-3_0.png?itok=nrK0jftc)
MPOX4
>90,000 cases have been reported globally since the start of the 2022-2023 outbreak >150 deaths have been reported globally since the start of the 2022-2023 outbreak
![about-vaccines-4](/sites/us.bnhcp.com/files/styles/large/public/2024-03/about-vaccines-4_0.png?itok=yBbYfyrs)
CHOLERA6
~1.3–4.0 million cases of cholera occur worldwide each year
Up to 143,000 deaths are attributed to cholera worldwide each year